Absci (NASDAQ:ABSI) Earns Buy Rating from Needham & Company LLC

Absci (NASDAQ:ABSI)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $7.00 price objective on the stock. Needham & Company LLC’s price target suggests a potential upside of 132.56% from the company’s previous close.

A number of other research analysts also recently commented on ABSI. HC Wainwright upped their price objective on shares of Absci from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a research report on Wednesday, January 21st. Finally, Morgan Stanley lowered shares of Absci from an “overweight” rating to an “equal weight” rating and set a $4.32 price target for the company. in a research report on Thursday, January 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.08.

Absci Stock Up 2.7%

Shares of Absci stock opened at $3.01 on Wednesday. Absci has a fifty-two week low of $2.01 and a fifty-two week high of $5.23. The business’s fifty day moving average is $2.78 and its two-hundred day moving average is $3.21. The firm has a market cap of $452.61 million, a PE ratio of -3.34 and a beta of 2.12.

Absci (NASDAQ:ABSI) last released its earnings results on Tuesday, March 24th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Absci had a negative net margin of 4,071.19% and a negative return on equity of 60.19%. The business had revenue of $0.65 million during the quarter, compared to analyst estimates of $1.38 million. Equities research analysts anticipate that Absci will post -0.89 EPS for the current year.

Insider Transactions at Absci

In other Absci news, insider Andreas Busch bought 100,000 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was purchased at an average price of $2.29 per share, with a total value of $229,000.00. Following the transaction, the insider owned 421,446 shares in the company, valued at $965,111.34. This trade represents a 31.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Sean Mcclain sold 26,761 shares of Absci stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $2.99, for a total transaction of $80,015.39. Following the transaction, the chief executive officer directly owned 8,334,567 shares in the company, valued at approximately $24,920,355.33. This trade represents a 0.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 10.49% of the company’s stock.

Hedge Funds Weigh In On Absci

Hedge funds have recently made changes to their positions in the business. Quarry LP purchased a new stake in Absci during the 3rd quarter worth $26,000. BNP Paribas Financial Markets raised its position in Absci by 91.2% in the second quarter. BNP Paribas Financial Markets now owns 11,287 shares of the company’s stock valued at $29,000 after purchasing an additional 5,385 shares during the period. Legal & General Group Plc lifted its stake in shares of Absci by 45.9% during the second quarter. Legal & General Group Plc now owns 11,690 shares of the company’s stock worth $30,000 after purchasing an additional 3,678 shares in the last quarter. HB Wealth Management LLC purchased a new stake in shares of Absci in the third quarter worth about $31,000. Finally, Principal Financial Group Inc. acquired a new stake in shares of Absci in the third quarter valued at about $31,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Absci News Summary

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Clinical progress: Absci reported successful dosing of the first three SAD cohorts in the ABS-201 HEADLINE trial with favorable emerging safety data — a tangible development that de‑risks the program and supports long‑term value for a drug‑discovery company. Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
• Positive Sentiment: Management narrative: Earnings‑call coverage highlights strategic advances and commentary on business priorities and cash/resource allocation that investors view as constructive for execution and partner interest. Absci Corp (ABSI) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience
• Neutral Sentiment: Full transcript available: The complete earnings‑call transcript provides detail on milestones, timelines and partnering discussions — useful for active investors but not an immediate catalyst by itself. Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Short‑interest data flagged as a “significant increase” in multiple reports but the underlying figures show zeros/NaN — the data appears unreliable and should be treated cautiously; no clear short squeeze/coverage signal. (Multiple short‑interest entries dated March 23–24.)
• Negative Sentiment: Earnings and revenue miss: ABSI reported Q4 EPS of ($0.20) vs. consensus (~($0.16)) and revenue of $0.65M vs. ~$1.38M — the miss and continued losses keep near‑term financials pressured and justify analyst caution. Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates

Absci Company Profile

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.